Starpharma sets December target for first human HER2 radiopharmaceutical trial

• DEP HER2-Lu Phase 1 study targeted to start in December 2026, subject to ethics approval
• A$37.9 million pro forma cash balance at 30 September, including the R&D tax incentive
• Petalion ownership increased to 66% for its FAP-targeted oncology program
• Genentech deal includes A$8.3 million upfront and potentially hundreds of millions in milestones